• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Shoshana Lipson on the Patient Perception of CGRP Inhibitors

Video

Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.

Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.

Transcript:

Are patients knowledgeable about [calcitonin gene-related peptide] CGRP inhibitors?

So, I would say it is kind of a mixed bag in terms of knowledge about the CGRP medications. Some people are very knowledgeable; they knew that they were coming, they had it planned, I personally had my doctor’s appointment set around a week after the first medication was approved. I knew it was coming and I knew I wanted to try it.

But then you’ve got people on the other end of the spectrum who are still saying “What? What’s CGRP and what does that stand for, what does it do, does this actually potentially help someone who has migraine?” So, we have the full range of the spectrum, and then again, trying to take that information and put it into simple language is just really, really crucial. So, we not only have my support group, but there are obviously also posts in the other migraine groups, but I’m also writing articles and speaking at different places just to educate patients about these new medications and also what they’re like in real-world application.

Related Videos
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Robert Zimmerman, MD
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Raajit Rampal, MD, PhD, screenshot
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.